Wed Oct 06 2021
Our treatment aims to prevent the dangerous overreaction of the immune system that results in patients becoming critically ill due to COVID-19. Using Biobank data, we identified CDK6 as a drug target. Inhibiting it will lower neutrophil cell count, which, when too high, is strongly linked with the severe and critical course of COVID-19. This potential treatment has been endorsed by Key Opinion Leaders from Harvard Medical School, Germany’s Robert-Koch-Institute and the University of Marburg. We are preparing a clinical phase 2b trial to show efficacy.